ATE291617T1 - Verfahren und konjugat zur behandlung von helicobacter pylori-infektionen - Google Patents
Verfahren und konjugat zur behandlung von helicobacter pylori-infektionenInfo
- Publication number
- ATE291617T1 ATE291617T1 AT98902712T AT98902712T ATE291617T1 AT E291617 T1 ATE291617 T1 AT E291617T1 AT 98902712 T AT98902712 T AT 98902712T AT 98902712 T AT98902712 T AT 98902712T AT E291617 T1 ATE291617 T1 AT E291617T1
- Authority
- AT
- Austria
- Prior art keywords
- conjugate
- pylori
- transport
- subject
- helicobacter pylori
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3636697P | 1997-01-24 | 1997-01-24 | |
| US08/848,844 US6030941A (en) | 1996-05-01 | 1997-04-30 | Polymer composition for delivering substances in living organisms |
| PCT/US1998/001393 WO1998032467A2 (en) | 1997-01-24 | 1998-01-23 | Method and conjugate for treating h. pylori infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE291617T1 true ATE291617T1 (de) | 2005-04-15 |
Family
ID=26713116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98902712T ATE291617T1 (de) | 1997-01-24 | 1998-01-23 | Verfahren und konjugat zur behandlung von helicobacter pylori-infektionen |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6124271A (de) |
| EP (1) | EP0973886B1 (de) |
| JP (1) | JP2001509167A (de) |
| AT (1) | ATE291617T1 (de) |
| AU (1) | AU742521B2 (de) |
| CA (1) | CA2278924A1 (de) |
| DE (1) | DE69829469D1 (de) |
| WO (1) | WO1998032467A2 (de) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7141244B1 (en) * | 1992-03-02 | 2006-11-28 | Chiron Srl | Helicobacter pylori proteins useful for vaccines and diagnostics |
| GB2303854B (en) * | 1994-07-01 | 1998-10-21 | Rican Limited | Helicobacter proteins and vaccines |
| WO1997025429A1 (en) * | 1996-01-04 | 1997-07-17 | Rican Limited | Helicobacter pylori bacterioferritin |
| GB9807721D0 (en) * | 1998-04-08 | 1998-06-10 | Chiron Spa | Antigen |
| US6190667B1 (en) * | 1998-06-30 | 2001-02-20 | Institut Pasteur | Methods of inhibiting Helicobacter pylori |
| AU6258999A (en) * | 1998-09-16 | 2000-04-03 | Vitagenix, Inc. | Compositions and methods of use of uptake mechanisms for diagnostic and therapeutic applications of oligonucleotides targeting bacteria |
| CA2388991A1 (en) * | 1998-11-11 | 2001-04-19 | Peter E. Nielsen | Conjugates between a peptides and a nucleic acid analog, such as a pna, lna or a morpholino |
| US6548651B1 (en) | 1998-11-11 | 2003-04-15 | Pantheco A/S | Modified peptide nucleic acid (PNA) molecules |
| AUPQ051099A0 (en) | 1999-05-24 | 1999-06-17 | Tachas, George Dr | Novel products and processes in treatment and/or prophylaxis |
| AU783874B2 (en) | 1999-11-29 | 2005-12-15 | Avi Biopharma, Inc. | Uncharged antisense oligonucleotides targeted to bacterial 16S and 23S PRNAS and their uses |
| KR20020079768A (ko) * | 2000-01-04 | 2002-10-19 | 에이브이아이 바이오파마 인코포레이티드 | 안티센스 항박테리아 세포분열 조성물 및 방법 |
| GB0005743D0 (en) * | 2000-03-10 | 2000-05-03 | Reckitt & Colmann Prod Ltd | Pharmaceutical compositions including alginates |
| CA2458854A1 (en) * | 2001-08-31 | 2003-03-06 | Chiron Srl | Helicobacter pylori vaccination |
| EP2351839A3 (de) | 2004-07-02 | 2011-10-05 | AVI BioPharma, Inc. | Antisinn antibakterielle verfahren und verbindungen |
| EP1935434A1 (de) * | 2006-12-19 | 2008-06-25 | Novosom AG | Konstruktion und Verwendung von transfektionsverstärkenden Elementen |
| WO2011018798A2 (en) * | 2009-08-14 | 2011-02-17 | Indian Association For The Cultivation Of Science | Morpholino-based antisense agent |
| US9050373B2 (en) | 2010-05-13 | 2015-06-09 | The Charlotte-Mecklenburg Hospital Authority | Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same |
| JP2014507143A (ja) | 2011-02-08 | 2014-03-27 | ザ シャーロット−メクレンバーグ ホスピタル オーソリティ ドゥーイング／ビジネス／アズ キャロライナズ ヘルスケア システム | アンチセンスオリゴヌクレオチド |
| US20150050245A1 (en) * | 2013-08-14 | 2015-02-19 | Tntgamble, Inc. | Methods and delivery system for beneficial additive and subtractive biological agents to promote balanced mammalian gastrointestinal flora |
| US11020417B2 (en) | 2015-06-04 | 2021-06-01 | Sarepta Therapeutics, Inc | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
| US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
| EP4221755A1 (de) * | 2020-10-01 | 2023-08-09 | Mississippi State University | Mit hexosephosphat konjugierte wirkstoffe sowie verfahren zu ihrer herstellung und verwendung |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5034506A (en) * | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| DE69232816T2 (de) * | 1991-11-26 | 2003-06-18 | Isis Pharmaceuticals, Inc. | Gesteigerte bildung von triple- und doppelhelices aus oligomeren mit modifizierten pyrimidinen |
| US5409903A (en) * | 1992-02-18 | 1995-04-25 | Urecap Corporation | Method and compositions for the treatment of H. pylori and dermatitis |
| US5426025A (en) * | 1992-05-28 | 1995-06-20 | Florida State University | Species-specific DNA probes for vibrio vulnificus methods and kits |
| US5434257A (en) * | 1992-06-01 | 1995-07-18 | Gilead Sciences, Inc. | Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages |
| US5574142A (en) * | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
| US5420019A (en) * | 1993-02-02 | 1995-05-30 | Xoma Corporation | Stable bactericidal/permeability-increasing protein muteins |
| CA2129565A1 (en) * | 1993-08-06 | 1995-02-07 | Hiroshi Tanimura | Oligonucleotide compounds, their production and use |
| US5434253A (en) * | 1994-03-21 | 1995-07-18 | Vanderbilt University | DNA encoding Helicobacter pylori recombinase |
| GB9505438D0 (en) * | 1995-03-17 | 1995-05-03 | Sod Conseils Rech Applic | Antisense oligonucleotides |
| AU729643B2 (en) * | 1996-05-01 | 2001-02-08 | Antivirals Inc. | Polypeptide conjugates for transporting substances across cell membranes |
-
1998
- 1998-01-23 AT AT98902712T patent/ATE291617T1/de not_active IP Right Cessation
- 1998-01-23 DE DE69829469T patent/DE69829469D1/de not_active Expired - Lifetime
- 1998-01-23 WO PCT/US1998/001393 patent/WO1998032467A2/en active IP Right Grant
- 1998-01-23 CA CA002278924A patent/CA2278924A1/en not_active Abandoned
- 1998-01-23 EP EP98902712A patent/EP0973886B1/de not_active Expired - Lifetime
- 1998-01-23 AU AU59305/98A patent/AU742521B2/en not_active Ceased
- 1998-01-23 JP JP53217498A patent/JP2001509167A/ja not_active Ceased
- 1998-01-23 US US09/012,198 patent/US6124271A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2278924A1 (en) | 1998-07-30 |
| AU742521B2 (en) | 2002-01-03 |
| JP2001509167A (ja) | 2001-07-10 |
| EP0973886B1 (de) | 2005-03-23 |
| EP0973886A2 (de) | 2000-01-26 |
| DE69829469D1 (de) | 2005-04-28 |
| AU5930598A (en) | 1998-08-18 |
| WO1998032467A3 (en) | 1998-09-17 |
| WO1998032467A2 (en) | 1998-07-30 |
| US6124271A (en) | 2000-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69829469D1 (de) | Verfahren und konjugat zur behandlung von helicobacter pylori-infektionen | |
| NO20033351L (no) | Fremgangsmater for a indusere organtransplantasjontoleranse og korrigering av hemoglobinopatier | |
| DK1242438T3 (da) | Cytotoksiske midler omfattende modificerede doxorubiciner og daunorubiciner og deres terapeutiske anvendelse | |
| ATE406453T1 (de) | Verfahren zür einführung und expression von genen in tierischen zellen | |
| PT1077688E (pt) | Sistema terapeutico transdermico contendo pergolide | |
| GB8801508D0 (en) | Translation of mrna | |
| WO2003068144A3 (en) | Cytotoxic agents | |
| ATE332918T1 (de) | Neoglycoproteine | |
| NO974194L (no) | Forbedringer i, eller vedrörende, organiske sammensetninger | |
| PE20030400A1 (es) | Productos en gel para la axila con componentes de bloque de agua | |
| EP1002877A3 (de) | Methode zur Genvervielfältigung | |
| DE50013093D1 (de) | Sequenz-spezifische dna-rekombination in eukaryotischen zellen | |
| RU94045151A (ru) | Биоразлагаемые полимеры и способ их получения | |
| ATE258596T1 (de) | Antigens-nukleinsäure enthaltende pharmazeutische zusammensetzung zur verbeugung und/oder behandlung von neuronalen verletzungen, entartungen und zellentot, und zur behandlung von neoplasmen | |
| IL142168A0 (en) | Mucosal originated drug delivery systems and animal applications | |
| ES2167939T3 (es) | Nuevas poliaminas, su preparacion y usos. | |
| EP0838224A3 (de) | Polymer - Arzneimittel Konjugate mit einer enzymspaltbaren Linker | |
| WO2000047231A3 (en) | Novel antisense inhibition of rad51 | |
| WO1999027086A1 (en) | Chimeric antisense oligonucleotides against tnf-alpha and their uses | |
| DE69834568D1 (de) | Vorrichtung zur gleichzeitigen austragung von wirkstoffen in den cervikal- und vaginalkanal | |
| Parekh et al. | Pancreatic regeneration after partial pancreatectomy | |
| WO1997046673A3 (en) | Inhibition of hiv-1 replication by antisense rna expression | |
| ATE235909T1 (de) | Biologisch kompatible und biologisch abbaubare zubereitungen enthaltend hyaluronsäure und deren derivate zur behandlung von geschwüren im verdauungsapparat | |
| NO20014815D0 (no) | Fremstilling av pankreatisk prokarboksypeptidase B, isoformer og muteiner derav og deres anvendelse | |
| DK1135164T3 (da) | Sammensætning til behandling af inflammation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |